BI 2536

Drug Profile

BI 2536

Alternative Names: BI 2536 BS; BI-2536

Latest Information Update: 07 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Benzamides; Piperidines; Pteridines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 07 Oct 2014 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (IV) (NCT02211833)
  • 24 Sep 2014 Discontinued - Phase-I for Non-Hodgkin's lymphoma in USA (IV)
  • 24 Sep 2014 Discontinued - Phase-I for Solid tumours in Germany (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top